$2.67
▼ -1.8% Today
as of Sep 4, 16:48 ET
Last 30 days
Recent Press Releases & News
Fortress Biotech, Inc. Q2 2026 Earnings Call Summary
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
Fortress Biotech: Q2 Earnings Snapshot
Overview
52-week range
$2.18
$4.53
21% of range
Avg surprise (last 2)
-28.7%
Avg reaction (last 2)
+5.2%
100% positive
Latest IV / EM
261%
EM ±40.7% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.08 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $2.82 | — | — | +687.5% | +3.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.11 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.46 | $-0.31 | -48.4% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.48 | $-0.44 | -9.1% | — | +7.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.76 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.73 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.04 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.94 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-3.65 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.21 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $16M | — | $18M | $16M | $13M | — | $15M |
| Cost of revenue | $6M | $6M | — | $6M | $5M | $5M | — | $4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-10M | $-8M | — | $-7M | $-36M | $-22M | — | $-22M |
| Net income | $-468,000 | $110M | — | $6M | $15M | $-11M | — | $-13M |
| EPS (diluted) | $-0.08 | $2.82 | — | $0.11 | $0.45 | $-0.48 | — | $-0.76 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $197M | $256M | $79M | $86M | $74M | $91M | $57M | $59M |
| Inventory | $8M | $9M | $10M | $12M | $13M | $12M | $14M | $12M |
| Total current assets | $246M | $295M | $124M | $119M | $110M | $127M | $90M | $86M |
| Total assets | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M |
| Long-term debt | $35M | $38M | $54M | $48M | $50M | $56M | — | $52M |
| Total liabilities | $111M | $154M | $123M | $116M | $123M | $146M | $146M | $140M |
| Total equity | $164M | $202M | $50M | $56M | $37M | $32M | $23M | $-13M |